Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest ICHD classification and diagnosis of migraine Stories

2010-12-23 13:31:00

LOS ANGELES, Dec. 23, 2010 /PRNewswire/ -- In a world where millions suffer daily from the debilitating pain of migraine headaches, one name stands out as the definitive leader in natural, safe and effective treatment. MigreLief by Akeso Health Sciences. Now, patients are raving about the amazing results of the new breakthrough product from Akeso. MigreLief+M (Menstrual) is the first of its kind supplement aimed at preventing migraines and other symptoms associated with a woman's...

2010-11-30 15:10:56

American Heart Association rapid access journal report Women with a history of migraine headache with aura (transient neurological symptoms, mostly visual impairments) are at increased risk of stroke. However, according to new research reported in Circulation: Journal of the American Heart Association stroke events in women with migraine with aura are more likely to have mild or no disability compared to those without migraine. In a new analysis of the Women's Health Study involving 27,852...

2010-10-12 18:21:40

Ohio University-led study suggests new option for headache pain management The combination of preventive medication and behavioral changes offered significant relief for 77 percent of the individuals enrolled in a study aimed at combating frequent, disabling migraine headaches, according to new Ohio University research published this week in the British Medical Journal. Though daily preventive medication and behavioral techniques individually have been shown to improve headache pain, the new...

2010-08-25 13:40:37

Research: Migraine with aura and risk of cardiovascular and all cause mortality in men and women: Prospective cohort study Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke, according to research published today on bmj.com. This is the first large population-based study showing a link between migraine and overall mortality as well as specific mortality. The...

2010-06-23 06:00:00

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX(TM) orally inhaled migraine therapy was effective irrespective...

2010-06-10 06:00:00

MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California. The late-breaker oral presentation titled "Utility of LEVADEX(TM) in Situations Where...

2010-06-07 08:00:00

CHICAGO, June 7 /PRNewswire/ -- If an average day begins as a hectic race to get the kids off to school and get to work on time, imagine starting that day with a migraine. For many of the nation's 30 million migraine sufferers whose lives are often turned upside down by their migraines, relief can't come soon enough. In a new survey released today by the National Headache Foundation (NHF), 3 in 4 migraine sufferers said their current medication doesn't work fast enough to get them back to...

a6bbaf9ac78c29022bf25475533943151
2010-04-14 10:35:00

While many migraine sufferers turn to prescription pain medication to relieve symptoms during an attack, a new study suggests that aspirin may be just as effective for dealing with the severe headaches that typically strike once or twice a month. A recent review completed by the Cochrane Collaboration, an organization comprised of health care specialists that complete randomized product trials, found that "a single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain...

2010-04-07 06:00:00

MOUNTAIN VIEW, Calif., April 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia. The data will be presented at the Annual Meeting of the American...

1fdde92d795cad4c5553fd26485bebc31
2010-03-26 10:30:00

In a survey of 1500 people that suffer painful migraines, researchers conclude that most sufferers have no idea when their next headaches will strike. Reuters reports that Dr. X. Henry Hu of Merck & Co., based out of West Point, Penn., said that this is important information, because early treatments with migraine drugs called triptans can help reduce migraine severity. Hu and his colleagues had about 1500 migraine sufferers complete a 10-minute survey, and then had them complete...